0001660334-26-000014
SEC filingQ1 revenue grew 46% to $5.0M from higher YCANTH deliveries and dispensed volumes, signaling commercial momentum, though operating losses widened 19.5% to -$9.7M due to elevated R&D costs tied to the Program amid ongoing cash usage.
Product revenue rose 46% year-over-year to $5.0M in Q1 FY2026, primarily from increased deliveries of YCANTH to distribution partners, aligned with higher dispensed applicator unit volumes. This growth underscores building commercial traction for the molluscum contagiosum treatment since launch. The Q4 2025 introduction of YCANTHRx—a non-dispensing pharmacy hub—streamlines the provider experience by routing prescriptions to in-network dispensing pharmacies regardless of patient insurance coverage. This operational enhancement likely facilitates faster adoption, converting prescriptions into shipments and bolstering scalable distribution. Investors can view this topline expansion as validation of YCANTH's market penetration, though monitoring payer mix and sustained volume trends remains key to assessing long-term uptake.